Takeda Pharmaceutical Co (BSP:TAKP34) LT-Debt-to-Total-Asset: 0.28 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:TAKP34 Takeda Pharmaceutical Co Ltd BSP:TAKP34
64 GF Score
Price R$82.32
GF Value R$70.13
! 9 Warning Signs
View Full Analysis

What is Takeda Pharmaceutical Co LT-Debt-to-Total-Asset?

Takeda Pharmaceutical Co BSP:TAKP34 64 LT-Debt-to-Total-Asset is 0.28 as of Mar. 2026. GuruFocus rates BSP:TAKP34 with a GF Score™ of 64/100 and a GF Value™ of R$70.13. The stock has 9 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Takeda Pharmaceutical Co's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.28.

Takeda Pharmaceutical Co's long-term debt to total assets ratio increased from Mar. 2025 (0.28) to Mar. 2026 (0.28). It may suggest that Takeda Pharmaceutical Co is progressively becoming more dependent on debt to grow their business.

Takeda Pharmaceutical Co  (BSP:TAKP34) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Takeda Pharmaceutical Co LT-Debt-to-Total-Asset Related Terms

Takeda Pharmaceutical Co LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Takeda Pharmaceutical Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Takeda Pharmaceutical Co LT-Debt-to-Total-Asset Chart

Takeda Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.31 0.29 0.30 0.28 0.28

Takeda Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.30 0.30 0.28 0.28
BSP:TAKP34
64GF Score
Takeda Pharmaceutical Co Ltd BSP:TAKP34
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Takeda Pharmaceutical Co LT-Debt-to-Total-Asset Calculation

Takeda Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (A: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (A: Mar. 2026 )/Total Assets (A: Mar. 2026 )
=144008.665/511202.367
=0.28

Takeda Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=144008.665/511202.367
=0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.28 mean?
Takeda Pharmaceutical Co (BSP:TAKP34) has a LT-Debt-to-Total-Asset of 0.28 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Takeda Pharmaceutical Co and its competitors.
Is Takeda Pharmaceutical Co's LT-Debt-to-Total-Asset too high?
Takeda Pharmaceutical Co's current LT-Debt-to-Total-Asset is 0.28. Overall, Takeda Pharmaceutical Co has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Takeda Pharmaceutical Co's LT-Debt-to-Total-Asset compare to ZTS and UTHR?
Takeda Pharmaceutical Co's LT-Debt-to-Total-Asset of 0.28 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Takeda Pharmaceutical Co and its competitors. Takeda Pharmaceutical Co's current LT-Debt-to-Total-Asset is 0.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takeda Pharmaceutical Co stock overvalued right now?
Takeda Pharmaceutical Co (BSP:TAKP34) has a current LT-Debt-to-Total-Asset of 0.28. The stock's GF Value™ is R$70.13, compared to a current price of R$82.32 — trading 17.4% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.28. Takeda Pharmaceutical Co's overall GF Score™ is 64/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Takeda Pharmaceutical Co (BSP:TAKP34), the current LT-Debt-to-Total-Asset is 0.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Takeda Pharmaceutical Co (BSP:TAKP34) Overvalued in 2026?

Based on GuruFocus' analysis, Takeda Pharmaceutical Co stock appears to be overvalued. The current stock price of R$82.32 is trading 17.4% above its estimated GF Value™ of R$70.13.

Key valuation signals for BSP:TAKP34:

  • LT-Debt-to-Total-Asset: 0.28
  • GF Value™: R$70.13 vs. price of R$82.32 (17.4% above fair value)
  • GF Score™: 64/100 with 9 warning signs

No single metric tells the full story. See the BSP:TAKP34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Takeda Pharmaceutical Co Business Description

Address 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
64GF Score

Get the complete analysis for BSP:TAKP34

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$82.32
Price
R$70.13
GF Value